article thumbnail

Boom, Now Bust: Budget Cuts and Layoffs Take Hold in Public Health

MedCity News

Local health department staffing grew by about 19% from 2019 to 2022, according to a report from the National Association of County and City Health Officials that studied 2,512 of the nation’s roughly 3,300 local departments.

Safety 299
article thumbnail

Are timely access and robust safety mutually exclusive?

pharmaphorum

And how can regulators balance timely access with robust safety? A new cross-sectional study has found that the FDA green lit 95% of the 89 new oncology therapies approved between 2010 and 2019 before the EMA, with the Europeans trailing the Americans by a median of 241 days. Accelerating safe access. appeared first on.

Safety 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gun violence is a national health issue

World of DTC Marketing

There was nearly a 30 percent increase in homicides between 2019 and 2020, making it the most significant one-year increase in six decades. Gun violence isn’t just a criminal justice issue; it’s a public health issue. He and Ninez Ponce, Ph.D. Gun violence kills people. These are health impacts,” Dr. Rodriguez says.

Doctors 46
article thumbnail

10 Trends for online health seekers

World of DTC Marketing

Hand flip wood cube change year 2019 to 2020. 10en : The most consumed pages on most pharma websites is safety information and pages that offer co-pay cards as people try to save money on Rx’s. In my opinion, this is due to pharma being sold on programmatic and the lack of investment in creative. 2020 trend concept.

Media 287
article thumbnail

Is DTC effective?

World of DTC Marketing

During the first quarter of 2020, the number of telehealth visits increased by 50%, compared with the same period in 2019, with a 154% increase in visits noted in surveillance week 13 in 2020, compared with the same period in 2019. For example, what percentage of patients experienced suicidal thoughts?

article thumbnail

Another Astellas gene therapy hits a safety hurdle

pharmaphorum

The safety of Astellas’ gene therapy portfolio has been thrust into the spotlight once again, after the FDA placed a clinical hold on a trial of its Pompe disease candidate AT845. The post Another Astellas gene therapy hits a safety hurdle appeared first on.

Safety 52
article thumbnail

FDA pushes Daiichi Sankyo’s quizartinib approval date by three months

Pharmaceutical Technology

Nonetheless, the agency did not require further efficacy and safety data in the application. The drug’s safety was generally manageable, and the rates of Grade 3 and higher treatment-emergent adverse events (TEAEs) were similar. The drug was also scrutinised in an FDA advisory committee (AdCom) meeting in May 2019.